Skip to main content
Top
Published in: Clinical Rheumatology 5/2009

01-05-2009 | Case Report

Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography

Authors: Burak Turgut, Peykan Turkcuoglu, Süleyman Serdar Koca, Orhan Aydemir

Published in: Clinical Rheumatology | Issue 5/2009

Login to get access

Abstract

Hydroxychloroquine (HCQ) that is widely used in the treatment of the connective tissue disorders can cause retinopathy. The fundus examination of a patient with systemic lupus erythematosus receiving HCQ revealed left incomplete bull's eye and pigmentary changes in macula in the right eye. Repeated visual field tests showed the paracentral and peripheral defects in the right eye and the pericentral ring scotoma in the left eye. Optical coherence tomography (OCT) scans revealed the photoreceptor loss, retina pigment epithelium (RPE) irregularities, and a cyst-like hypo reflective space over RPE layer on the nasal perifoveal region in the left eye. On the ophthalmoscopic examination, the perifoveal pigmentation was not altered after the discontinuation of HCQ. However, the bilateral visual field defects were improved and the photoreceptor destruction and cyst-like hyporeflective space disappeared in the left eye. Mild RPE irregularities remained in both eyes as revealed by OCT scans. Even if OCT is used to evaluate the regression of HCQ retinopathy, it only shows advanced stage of retinopathy.
Literature
1.
go back to reference Yam JC, Kwok AK (2006) Ocular toxicity of hydroxychloroquine. Hong Kong Med J 12:294–304PubMed Yam JC, Kwok AK (2006) Ocular toxicity of hydroxychloroquine. Hong Kong Med J 12:294–304PubMed
2.
go back to reference Wetterholm DH, Winter FC (1964) Histopathology of chloroquine retinal toxicity. Arch Ophthalmol 71:82–87PubMed Wetterholm DH, Winter FC (1964) Histopathology of chloroquine retinal toxicity. Arch Ophthalmol 71:82–87PubMed
3.
go back to reference Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL (1991) Hydroxychloroquine retinopathy. Am J Ophthalmol 112:528–534PubMed Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL (1991) Hydroxychloroquine retinopathy. Am J Ophthalmol 112:528–534PubMed
4.
go back to reference Easterbrook M (1993) The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 23:62S–67SCrossRef Easterbrook M (1993) The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 23:62S–67SCrossRef
5.
go back to reference Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF (2002) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 109:1377–1382PubMedCrossRef Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF (2002) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 109:1377–1382PubMedCrossRef
6.
go back to reference Rodriguez-Padilla JA, Hedges TR 3rd, Monson B et al (2007) High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol 125:775–780PubMedCrossRef Rodriguez-Padilla JA, Hedges TR 3rd, Monson B et al (2007) High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol 125:775–780PubMedCrossRef
Metadata
Title
Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography
Authors
Burak Turgut
Peykan Turkcuoglu
Süleyman Serdar Koca
Orhan Aydemir
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1108-0

Other articles of this Issue 5/2009

Clinical Rheumatology 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine